ACR Convergence 2025| Video: Rheuminations on Milestones & Ageism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Guidance

Subcategories:EthicsLegal UpdatesLegislation & AdvocacyResearch Rheum

Figure 2: High-resolution computed tomography showed evidence of interstitial lung disease.

High-resolution computed tomography shows evidence of ILD.

The ACR/CHEST ILD Guidelines in Practice, a video
In collaboration with the American College of Chest Physicians, the ACR released two new comprehensive guidelines aimed at improving the screening, monitoring, and treatment of patients with interstitial lung disease (ILD) secondary to systemic autoimmune rheumatic diseases (SARDs). Recently, Sindhu R. Johnson, MD, PhD, professor of medicine at the University of Toronto, Canada, director of the Toronto Scleroderma Program and principal investigator for the guideline, and Elana J. Bernstein, MD, MSc, Florence Irving associate professor of medicine in the Division of Rheumatology at Columbia University, New York City, and co-first author, presented a webinar to talk about how the guidelines were developed and present some of the recommendations and their rationale: Watch the recording now!

 

3 AC&R Study Summaries: RA & Frailty, Hydroxychloroquine Can Protect Kidneys in Lupus Nephritis, & PT for Knee OA

Arthritis Care & Research  |  November 11, 2025

Research on PT for knee OA, HCQ’s protective role in lupus nephritis & the link between RA disease activity & frailty.

Why Target B Cells in SSc-ILD?

Katie Robinson  |  November 11, 2025

In a recent Arthritis & Rheumatology review article, three experts discuss the use of immunosuppressants to target B cells in a patient with systemic sclerosis-interstitial lung disease.

Rheuminations: Address Ableism, Improve Care for All Patients

Bharat Kumar, MD, MME, FACP, FAAAAI, RhMSUS  |  November 10, 2025

Ableism—discrimination against those with disabilities—distorts diagnostic reasoning & erodes patient trust. How can rheumatologists address this bias?

New Rheumatoid Arthritis Risk Stratification Criteria Released

Ruth Jessen Hickman, MD  |  November 10, 2025

New EULAR/ACR criteria help stratify RA risk in patients with arthralgia. Learn how these criteria guide earlier interventions & improve trial rigor.

The Microbiome’s Impact on Rheumatoid Arthritis & Drug Response

Ruth Jessen Hickman, MD  |  November 7, 2025

The gut microbiome may trigger RA & predict methotrexate response. ACR Convergence 2025 experts discuss pathogenesis & drug efficacy.

President’s Corner: Dr. Langford’s Reflections on the ACR’s 2025

Carol A. Langford, MD, MHS  |  November 5, 2025

Dr. Langford’s final column reflects on 2025’s advocacy, challenges & member teamwork. Click through to read the outgoing ACR president’s parting thoughts.

Calcium Pyrophosphate Deposition Disease Diagnosis & Treatment Gaps Remain

Kurt Ullman  |  November 3, 2025

CPPD diagnosis is difficult & treatments are limited. Experts review radiology challenges, off-label options like colchicine, & emerging biologics.

How Lymphatic Drainage Controls Synovial Inflammation

Michael Cammarata, MD  |  November 2, 2025

Why do lymphatics fail in inflammatory arthritis? Research from ACR Convergence 2025 points to a network of telocytes & mast cells that control synovial drainage.

The Rheum Advocate: A Fresh Look for the Same Trusted Voice

From the College  |  October 21, 2025

Starting Nov. 13, the long-running ACR@Work newsletter is transforming into The Rheum Advocate, delivering the latest updates on advocacy, policy developments, clinical practice support and the issues that matter most to rheumatology professionals.

ACR Delegation to Address AI, Non-Compete Agreements at Interim AMA House of Delegates Meeting

From the College  |  October 21, 2025

The ACR’s resolutions at the Interim HOD meeting, held Nov. 14–18, will address non-compete agreements as well as the use of artificial intelligence (AI) in prior authorization processes.

  • 1
  • 2
  • 3
  • …
  • 249
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences